Skip to content

Study · Animal study (in vivo) · rat · 2021

8 results

The novel GLP-1/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury.

Bai B, Li D, Xue G, Feng P, Wang M, Han Y, Wang Y, Hölscher C

Nutrition, metabolism, and cardiovascular diseases : NMCD12 Sept 2020Cited by 18 (Europe PMC)

PMID33500109 (opens in a new tab)DOI10.1016/j.numecd.2020.09.002 (opens in a new tab)PepBankPUB-33500109
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats with cerebral ischemia-reperfusion injury, liraglutide treatment significantly reduced the neurological dysfunction score.

    In plain wordsIn rats with diabetes and stroke-like brain injury, liraglutide lowered the score for nerve and movement problems.

    Peptide
    Liraglutide
    Outcome
    DecreaseNeurological deficit score
    Study

    ratn = 18

    Streptozotocin-induced diabetic Sprague-Dawley rats with middle cerebral artery occlusion and reperfusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mmol/kg once daily · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    The DA3-CH-treated and liraglutide-treated groups showed significantly reduced scores of neurological dysfunction and cerebral infarction size, and reduced the expression of ERS markers GRP78, CHOP and Caspase-12, and the expression of apoptosis marker bax.
    2 context sentences
    Summary · context
    72 Sprague-Dawley (SD) male rats were randomly divided into 4 groups: ① blank group (Sham group, n = 18); model group (Saline group, n = 18); DA3 treatment group (DA3 group, n = 18); liraglutide treatment group (Lir group, n = 18).
    Summary · context
    After the successful membrane formation of diabetes, DA3-CH and liraglutide (10 mmol/kg, once-daily for 14 days) were injected intraperitoneally.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats with cerebral ischemia-reperfusion injury, liraglutide treatment significantly reduced cerebral infarction size.

    In plain wordsIn rats with diabetes and stroke-like brain injury, liraglutide made the area of brain damage smaller.

    Peptide
    Liraglutide
    Outcome
    DecreaseCerebral infarct size
    Study

    ratn = 18

    Streptozotocin-induced diabetic Sprague-Dawley rats with middle cerebral artery occlusion and reperfusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mmol/kg once daily · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    The DA3-CH-treated and liraglutide-treated groups showed significantly reduced scores of neurological dysfunction and cerebral infarction size, and reduced the expression of ERS markers GRP78, CHOP and Caspase-12, and the expression of apoptosis marker bax.
    2 context sentences
    Summary · context
    72 Sprague-Dawley (SD) male rats were randomly divided into 4 groups: ① blank group (Sham group, n = 18); model group (Saline group, n = 18); DA3 treatment group (DA3 group, n = 18); liraglutide treatment group (Lir group, n = 18).
    Summary · context
    After the successful membrane formation of diabetes, DA3-CH and liraglutide (10 mmol/kg, once-daily for 14 days) were injected intraperitoneally.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In diabetic rats with cerebral ischemia-reperfusion injury, liraglutide treatment reduced expression of the endoplasmic reticulum stress marker GRP78.

    In plain wordsIn rats with diabetes and stroke-like brain injury, liraglutide lowered a cell stress marker called GRP78.

    Peptide
    Liraglutide
    Outcome
    DecreaseGRP78 expression
    Study

    ratn = 18

    Streptozotocin-induced diabetic Sprague-Dawley rats with middle cerebral artery occlusion and reperfusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mmol/kg once daily · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    The DA3-CH-treated and liraglutide-treated groups showed significantly reduced scores of neurological dysfunction and cerebral infarction size, and reduced the expression of ERS markers GRP78, CHOP and Caspase-12, and the expression of apoptosis marker bax.
    2 context sentences
    Summary · context
    72 Sprague-Dawley (SD) male rats were randomly divided into 4 groups: ① blank group (Sham group, n = 18); model group (Saline group, n = 18); DA3 treatment group (DA3 group, n = 18); liraglutide treatment group (Lir group, n = 18).
    Summary · context
    After the successful membrane formation of diabetes, DA3-CH and liraglutide (10 mmol/kg, once-daily for 14 days) were injected intraperitoneally.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In diabetic rats with cerebral ischemia-reperfusion injury, liraglutide treatment reduced expression of the endoplasmic reticulum stress marker CHOP.

    In plain wordsIn rats with diabetes and stroke-like brain injury, liraglutide lowered a cell stress marker called CHOP.

    Peptide
    Liraglutide
    Outcome
    DecreaseCHOP expression
    Study

    ratn = 18

    Streptozotocin-induced diabetic Sprague-Dawley rats with middle cerebral artery occlusion and reperfusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mmol/kg once daily · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    The DA3-CH-treated and liraglutide-treated groups showed significantly reduced scores of neurological dysfunction and cerebral infarction size, and reduced the expression of ERS markers GRP78, CHOP and Caspase-12, and the expression of apoptosis marker bax.
    2 context sentences
    Summary · context
    72 Sprague-Dawley (SD) male rats were randomly divided into 4 groups: ① blank group (Sham group, n = 18); model group (Saline group, n = 18); DA3 treatment group (DA3 group, n = 18); liraglutide treatment group (Lir group, n = 18).
    Summary · context
    After the successful membrane formation of diabetes, DA3-CH and liraglutide (10 mmol/kg, once-daily for 14 days) were injected intraperitoneally.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In diabetic rats with cerebral ischemia-reperfusion injury, liraglutide treatment reduced expression of the endoplasmic reticulum stress marker Caspase-12.

    In plain wordsIn rats with diabetes and stroke-like brain injury, liraglutide lowered a cell stress marker called Caspase-12.

    Peptide
    Liraglutide
    Outcome
    DecreaseCaspase-12 expression
    Study

    ratn = 18

    Streptozotocin-induced diabetic Sprague-Dawley rats with middle cerebral artery occlusion and reperfusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mmol/kg once daily · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    The DA3-CH-treated and liraglutide-treated groups showed significantly reduced scores of neurological dysfunction and cerebral infarction size, and reduced the expression of ERS markers GRP78, CHOP and Caspase-12, and the expression of apoptosis marker bax.
    2 context sentences
    Summary · context
    72 Sprague-Dawley (SD) male rats were randomly divided into 4 groups: ① blank group (Sham group, n = 18); model group (Saline group, n = 18); DA3 treatment group (DA3 group, n = 18); liraglutide treatment group (Lir group, n = 18).
    Summary · context
    After the successful membrane formation of diabetes, DA3-CH and liraglutide (10 mmol/kg, once-daily for 14 days) were injected intraperitoneally.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In diabetic rats with cerebral ischemia-reperfusion injury, liraglutide treatment reduced expression of the apoptosis marker bax.

    In plain wordsIn rats with diabetes and stroke-like brain injury, liraglutide lowered bax, a marker of cell death.

    Peptide
    Liraglutide
    Outcome
    DecreaseBax expression (apoptosis marker)
    Study

    ratn = 18

    Streptozotocin-induced diabetic Sprague-Dawley rats with middle cerebral artery occlusion and reperfusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mmol/kg once daily · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    The DA3-CH-treated and liraglutide-treated groups showed significantly reduced scores of neurological dysfunction and cerebral infarction size, and reduced the expression of ERS markers GRP78, CHOP and Caspase-12, and the expression of apoptosis marker bax.
    2 context sentences
    Summary · context
    72 Sprague-Dawley (SD) male rats were randomly divided into 4 groups: ① blank group (Sham group, n = 18); model group (Saline group, n = 18); DA3 treatment group (DA3 group, n = 18); liraglutide treatment group (Lir group, n = 18).
    Summary · context
    After the successful membrane formation of diabetes, DA3-CH and liraglutide (10 mmol/kg, once-daily for 14 days) were injected intraperitoneally.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In diabetic rats with cerebral ischemia-reperfusion injury, the anti-apoptotic marker bcl-2 increased significantly after liraglutide treatment.

    In plain wordsIn rats with diabetes and stroke-like brain injury, liraglutide raised bcl-2, a marker that protects cells from death.

    Peptide
    Liraglutide
    Outcome
    IncreaseBcl-2 expression (anti-apoptotic marker)
    Study

    ratn = 18

    Streptozotocin-induced diabetic Sprague-Dawley rats with middle cerebral artery occlusion and reperfusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mmol/kg once daily · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    The DA3-CH-treated and liraglutide-treated groups showed significantly reduced scores of neurological dysfunction and cerebral infarction size, and reduced the expression of ERS markers GRP78, CHOP and Caspase-12, and the expression of apoptosis marker bax. Anti-apoptotic markers bcl-2 and neuronal…
    2 context sentences
    Summary · context
    72 Sprague-Dawley (SD) male rats were randomly divided into 4 groups: ① blank group (Sham group, n = 18); model group (Saline group, n = 18); DA3 treatment group (DA3 group, n = 18); liraglutide treatment group (Lir group, n = 18).
    Summary · context
    After the successful membrane formation of diabetes, DA3-CH and liraglutide (10 mmol/kg, once-daily for 14 days) were injected intraperitoneally.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats with cerebral ischemia-reperfusion injury, neuronal numbers increased significantly after liraglutide treatment.

    In plain wordsIn rats with diabetes and stroke-like brain injury, liraglutide treatment was followed by more nerve cells.

    Peptide
    Liraglutide
    Outcome
    IncreaseNeuronal numbers
    Study

    ratn = 18

    Streptozotocin-induced diabetic Sprague-Dawley rats with middle cerebral artery occlusion and reperfusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mmol/kg once daily · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    The DA3-CH-treated and liraglutide-treated groups showed significantly reduced scores of neurological dysfunction and cerebral infarction size, and reduced the expression of ERS markers GRP78, CHOP and Caspase-12, and the expression of apoptosis marker bax. Anti-apoptotic markers bcl-2 and neuronal…
    2 context sentences
    Summary · context
    72 Sprague-Dawley (SD) male rats were randomly divided into 4 groups: ① blank group (Sham group, n = 18); model group (Saline group, n = 18); DA3 treatment group (DA3 group, n = 18); liraglutide treatment group (Lir group, n = 18).
    Summary · context
    After the successful membrane formation of diabetes, DA3-CH and liraglutide (10 mmol/kg, once-daily for 14 days) were injected intraperitoneally.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.